Intercellular adhesion molecule 1 links glioblastoma biology to a scalable prognostic model integrating clinical, imaging, and molecular features
Open Access
- 12 January 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Abstract
Background: Glioblastoma (GB) exhibits marked tumor microenvironmental heterogeneity, contributing to both therapy resistance and poor survival outcomes. Intercellular adhesion molecule 1 (ICAM1) is an inflammation-associated adhesion molecule implicated in immune-stromal interactions, but its clinical and biological significance in GB remains incompletely defined. Methods: We performed ICAM1 immunohistochemistry, bulk RNA sequencing, DNA methylation analysis, single-nucleus RNA sequencing, and preoperative MRI-derived morphologic feature analysis across multi-institutional cohorts of treatment-naïve IDH-wildtype GB. Results: High ICAM1 expression at both transcript and protein levels is associated with shorter overall survival, particularly within the mesenchymal transcriptional subtype. ICAM1 expression is inversely associated with promoter methylation. Single-nucleus RNA-sequencing analysis shows that ICAM1-high tumors are enriched for mesenchymal, hypoxia, stress-associated, and immunosuppressive myeloid programs, suggesting that ICAM1 reflects a multicompartment inflammatory tumor ecosystem. ICAM1 expression, tumor surface irregularity, and patient age are independently prognostic and minimally correlated, capturing complementary clinical, imaging, and molecular features of GB biology. When combined, our Clinical-Imaging-Molecular (CIM) framework refines outcome prediction across independent GB cohorts using routinely available clinical data, conventional imaging, and standard immunohistochemistry. Conclusions: ICAM1 characterizes an immune-remodeled, stress-adapted GB ecosystem associated with poor clinical outcomes. Integrating patient age, surface irregularity, and ICAM1 expression yields a scalable and clinically accessible prognostic framework for GB, supporting tailored outcome prediction, particularly in low- and middle-resource settings without routine access to advanced molecular profiling.Keywords
Funding Information
- Terry Fox Research Institute (TFRI-1090-P2)
This publication has 55 references indexed in Scilit:
- Comparison of Three Automated Measurements of Ventricular Volumes of the BrainJournal of Imaging Informatics in Medicine, 2026
- Glioblastoma cells secrete ICAM1 via FASN signaling to promote glioma-associated macrophage infiltrationCellular Signalling, 2025
- Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergyAngiogenesis, 2022
- Soluble ICAM‐1 a Pivotal Communicator between Tumors and Macrophages, Promotes Mesenchymal Shift of GlioblastomaAdvanced Science, 2021
- ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesisJournal of Leukocyte Biology, 2020
- An Integrative Model of Cellular States, Plasticity, and Genetics for GlioblastomaCell, 2019
- Morphological MRI-based features provide pretreatment survival prediction in glioblastomaEuropean Radiology, 2018
- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the MicroenvironmentCancer Cell, 2018
- Intercellular adhesion molecule‐1 (ICAM‐1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesionInternational Journal of Cancer, 2013
- ICAM-1 expression determines malignant potential of cancerSurgery, 2007